肿瘤免疫组库研究促进癌症疫苗研究  

Tumor immune repertoire study promotes the research of tumor vaccine

作　　者：张蒙[1] 王倚天[1] 谢良富 蔡志明[1] 吴松[1,2] 

机构地区：[1]安徽医科大学深圳市第二人民医院临床医学院,深圳518000 [2]中山大学中山医学院,广州510000

出　　处：《生命科学》2015年第2期120-126,共7页Chinese Bulletin of Life Sciences

基　　金：国家重点基础研究发展计划("973"项目)(2014CB745200);国家自然科学基金项目(81301740);深圳市基础研究项目(JCYJ20130401114928183;JCYJ20130401114715714)

摘　　要：人体免疫系统是抵御病原菌侵犯、防止肿瘤发生最重要的保卫系统。针对免疫系统中T/B淋巴细胞的免疫组库研究,找出肿瘤与TCR或BCR之间的关系,发现肿瘤特异性标志物,从而推动肿瘤特异性诊断、治疗及预后评估等的发展,特别是在肿瘤免疫组库研究基础上衍生出的癌症疫苗,可以在患者体内实现诱导定向肿瘤免疫反应,为肿瘤患者的治疗带来新希望。现从肿瘤免疫组库、癌症疫苗的研究进展等方面来阐述。The immune system plays a vital role in the prevention of pathogen invasion and tumor development. The immune repertoire study, which targets T/B lymphocytes, can propel the development of tumor-specific diagnosis, treatment, evaluation of prognosis with the discovery of tumor-specific biomarkers after the correlation between tumor and TCR/BCR is elucidated. The tumor vaccine, derived from the tumor immune repertoire study, can induce a tumor-oriented immune response in patients, thus providing a new treatment for cancer. In this paper, we conducted a systematic review on the tumor immune repertoire study and demonstrated the advance in tumor vaccine research.

关 键 词：免疫组库 肿瘤 癌症疫苗 

分 类 号：R730.3[医药卫生—肿瘤]